News for Healthier Living

More Than Half of U.S. Adults Could Benefit From GLP-1 Medications, Researchers Find

In a new analysis of national data, researchers at the Richard A. and Susan F. Smith Center for Outcomes Research at Beth Israel Deaconess Medical Center (BIDMC) estimated that 137 million U.S. adults, more than half of all adults, are eligible for semagludtide for weight loss, diabetes management, or prevention of recurrent cardiovascular events.

November 20, 2024


November 21 2024

November 20 2024

November 19 2024

November 18 2024

November 17 2024

November 16 2024

November 15 2024

November 14 2024

November 13 2024

November 12 2024

November 11 2024

November 10 2024

November 9 2024

November 8 2024